IOL Chemicals and Pharmaceuticals Limited Expertise in Lamotrigine


Fully backward integrated process and Different PSD grades are available within the same process.

Highest quality standards that meet all Pharmacopeial and ICH requirements to ensure a place in the highest echelons of the Lamotrigine API markets.

Contact Us

Mechanism of Action

Lamotrigine API acts by inhibiting sodium currents by selective binding to the inactive sodium channel, suppressing the release of the excitatory amino acid, glutamate.

The active pharmaceutical ingredient covalently binds to the H+/K+ ATP pump to inhibit gastric acid and basal acid secretion In the gastric parietal cell of the stomach. The covalent binding prevents acid secretion for up to 24 hours.

Lamotrigine API binds to Adenosine A1/A2 receptors, α1/α2/β adrenergic receptors, dopamine D1/D2 receptors, GABA A/B receptors, histamine H1 receptors, κ-opioid receptor (KOR), mACh receptors and serotonin 5-HT2 receptors with an IC50>100 µM. Weak inhibitory effects were observed at sigma opioid receptors.

An in vivo study among the Lamotrigine API market revealed evidence that Lamotrigine API inhibits Cav2.3 (R-type) calcium currents, which may also contribute to its anticonvulsant effects.

arrowimg

Indication

The main therapeutic indications of the Lamotrigine API are:

Lamotrigine API is used as adjunctive therapy for seizures and is indicated for the maintenance treatment of bipolar I disorder, delaying the time to mood episodes (which may include mania, hypomania, depression, and mixed episodes) in adults.

Lamotrigine, as an active pharmaceutical ingredient is used alone or with other medications to prevent and control seizures.

Download Our Brochure to Know More